NeoGenomics, Inc. Hits New 52-Week High of $16.92, Showcasing Strong Growth

NeoGenomics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 16.92 on August 10, 2026. This achievement marks a notable increase from its 52-week low of USD 5.65, reflecting a robust performance over the past year. In the last year, NeoGenomics has demonstrated a performance increase of 24.85%, outperforming the S&P 500, which recorded a gain of 21.34%. The company's market capitalization stands at USD 933 million, indicating its position as a small-cap entity within the industry. Despite being loss-making, NeoGenomics maintains a debt-to-equity ratio of 0.22, suggesting a relatively low level of debt compared to equity. The company's price-to-book ratio is currently at 1.12, providing insight into its valuation relative to its assets. As NeoGenomics continues to navigate the competitive landscape of pharmaceuticals and biotechnology, this recent price milestone underscores its evolving market presence.